Ignite Creation Date:
2024-05-06 @ 4:28 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04996823
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2021-08-02
Brief Title:
Axitinib Ipilimumab in Advanced Melanoma
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Phase 2 Study of Axitinib Ipilimumab in Advanced Melanoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma
Detailed Description:
The safety and tolerability of the combination of ipilimumab and axitinib will be tested in advanced melanoma patients who are intolerablerefractory to anti-PD-1PD-L1 therapy and have not previously received treatment with ipilimumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 63403991 | OTHER | Pfizer | None |